BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced the successful completion of a full study on its localized pain management product, Probudur™, conducted in partnership with the U.S. Army Institute of Surgical Research (USAISR). This research aimed to evaluate Probudur’s ability to reduce pain behaviors in a rat model of incisional pain.
The study, performed under a Cooperative Research and Development Agreement (CRADA) with USAISR, replicated the methodology of an earlier pilot study. Researchers assessed the effects of Probudur alongside free bupivacaine, EXPAREL®, and saline as a control. Various concentrations of Probudur were injected around the incision site, demonstrating significant reductions in pain behaviors.
“These positive results are consistent with what we at Virpax have previously observed and we are encouraged by these findings,” said Jatinder Dhaliwal, Chief Executive Officer of Virpax.
Probudur is being developed to provide effective, long-lasting pain control during and after surgery, potentially reducing or even eliminating the need for opioids. Unlike traditional anesthetics, Probudur works by binding to sodium channels to block pain signals from reaching the brain and has shown impressive results in preclinical studies. The rat model revealed pain mitigation for up to five days, while in vitro studies demonstrated bupivacaine release lasting up to six days.
The technology’s capability for extended pain relief marks a significant leap in perioperative care and positions Probudur as a safer alternative for managing post-surgical pain with less reliance on opioids.
With these promising findings, Virpax will continue advancing Probudur’s development. The company remains focused on bringing this innovative solution to market, aiming to improve outcomes for surgical patients and alleviate dependency on opioid-based treatments.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.